Literature DB >> 12446689

Residues glutamate 216 and aspartate 301 are key determinants of substrate specificity and product regioselectivity in cytochrome P450 2D6.

Mark J I Paine1, Lesley A McLaughlin, Jack U Flanagan, Carol A Kemp, Michael J Sutcliffe, Gordon C K Roberts, C Roland Wolf.   

Abstract

Cytochrome P450 2D6 (CYP2D6) metabolizes a wide range of therapeutic drugs. CYP2D6 substrates typically contain a basic nitrogen atom, and the active-site residue Asp-301 has been implicated in substrate recognition through electrostatic interactions. Our recent computational models point to a predominantly structural role for Asp-301 in loop positioning (Kirton, S. B., Kemp, C. A., Tomkinson, N. P., St.-Gallay, S., and Sutcliffe, M. J. (2002) Proteins 49, 216-231) and suggest a second acidic residue, Glu-216, as a key determinant in the binding of basic substrates. We have evaluated the role of Glu-216 in substrate recognition, along with Asp-301, by site-directed mutagenesis. Reversal of the Glu-216 charge to Lys or substitution with neutral residues (Gln, Phe, or Leu) greatly decreased the affinity (K(m) values increased 10-100-fold) for the classical basic nitrogen-containing substrates bufuralol and dextromethorphan. Altered binding was also manifested in significant differences in regiospecificity with respect to dextromethorphan, producing enzymes with no preference for N-demethylation versus O-demethylation (E216K and E216F). Neutralization of Asp-301 to Gln and Asn had similarly profound effects on substrate binding and regioselectivity. Intriguingly, removal of the negative charge from either 216 or 301 produced enzymes (E216A, E216K, and D301Q) with elevated levels (50-75-fold) of catalytic activity toward diclofenac, a carboxylate-containing CYP2C9 substrate that lacks a basic nitrogen atom. Activity was increased still further (>1000-fold) upon neutralization of both residues (E216Q/D301Q). The kinetic parameters for diclofenac (K(m) 108 microm, k(cat) 5 min(-1)) along with nifedipine (K(m) 28 microm, k(cat) 2 min(-1)) and tolbutamide (K(m) 315 microm, k(cat) 1 min(-1)), which are not normally substrates for CYP2D6, were within an order of magnitude of those observed with CYP3A4 or CYP2C9. Neutralizing both Glu-216 and Asp-301 thus effectively alters substrate recognition illustrating the central role of the negative charges provided by both residues in defining the specificity of CYP2D6 toward substrates containing a basic nitrogen.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12446689     DOI: 10.1074/jbc.M209519200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  CYP isoform specificity toward drug metabolism: analysis using common feature hypothesis.

Authors:  M Ramesh; Prasad V Bharatam
Journal:  J Mol Model       Date:  2011-05-12       Impact factor: 1.810

2.  Using a homology model of cytochrome P450 2D6 to predict substrate site of metabolism.

Authors:  Rayomand J Unwalla; Jason B Cross; Sumeet Salaniwal; Adam D Shilling; Louis Leung; John Kao; Christine Humblet
Journal:  J Comput Aided Mol Des       Date:  2010-04-02       Impact factor: 3.686

3.  IDSite: An accurate approach to predict P450-mediated drug metabolism.

Authors:  Jianing Li; Severin T Schneebeli; Joseph Bylund; Ramy Farid; Richard A Friesner
Journal:  J Chem Theory Comput       Date:  2011-11-08       Impact factor: 6.006

4.  Understanding the determinants of selectivity in drug metabolism through modeling of dextromethorphan oxidation by cytochrome P450.

Authors:  Julianna Oláh; Adrian J Mulholland; Jeremy N Harvey
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-28       Impact factor: 11.205

5.  Crystal Structures of Drug-Metabolizing CYPs.

Authors:  D Fernando Estrada; Amit Kumar; Christopher S Campomizzi; Natalie Jay
Journal:  Methods Mol Biol       Date:  2021

6.  Ligand-Based Site of Metabolism Prediction for Cytochrome P450 2D6.

Authors:  Patrik Rydberg; Lars Olsen
Journal:  ACS Med Chem Lett       Date:  2011-11-07       Impact factor: 4.345

7.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions.

Authors:  J-D Maréchal; C A Kemp; G C K Roberts; M J I Paine; C R Wolf; M J Sutcliffe
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

9.  Phe120 contributes to the regiospecificity of cytochrome P450 2D6: mutation leads to the formation of a novel dextromethorphan metabolite.

Authors:  Jack U Flanagan; Jean-Didier Maréchal; Richard Ward; Carol A Kemp; Lesley A McLaughlin; Michael J Sutcliffe; Gordon C K Roberts; Mark J I Paine; C Roland Wolf
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

Review 10.  Recent Structural Insights into Cytochrome P450 Function.

Authors:  F Peter Guengerich; Michael R Waterman; Martin Egli
Journal:  Trends Pharmacol Sci       Date:  2016-06-04       Impact factor: 14.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.